ETV6 at 12p13 is rearranged in a variety of haematological malignancies and solid tumours, with more than 20 different partners having been reported. These fusions result in either chimeric proteins or activation of the partner gene. However, there are a few examples of abnormalities resulting in truncated, and most likely, unproductive ETV6 proteins, suggesting that haploinsufficiency of ETV6 and/or the partner is leukemogenic. We present a novel ETV6 rearrangement, identified in a paediatric pre-B acute lymphoblastic leukaemia. FISH and molecular genetic analyses revealed a fusion of ETV6 and BAZ2A (at 12q13), generated through a cryptic rearrangement between 12p13 and 12q13, consisting of exons 1 and 2 of ETV6 and a sequence from intron 1 of BAZ2A. This transcript is not expected to produce any chimeric protein, but may encode a truncated form of ETV6, containing the first 54 amino acids (aa), followed by 16 aa from the 3´fusion sequence, reminiscent of ETV6 fusions with MDS2, LOC115548, PER1, and STL. The rearrangement might also modify the regulation of BAZ2A by either activating a cryptic promoter or by coming under the control of the ETV6
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Introduction
Cytogenetic analyses are today an integral part of the clinical management of patients with haematological malignancies, yielding diagnostic as well as prognostic information (Johansson et al, 2004; Mrózek et al, 2004) . Furthermore, the detection of acquired chromosomal abnormalities, in particular translocations and inversions, has paved the way for identifying genes, located at the breakpoints, that if rearranged or otherwise deregulated are intimately associated with the leukemogenic process (Rowley, 2001) . In fact, more than 200 such rearranged genes have been identified in haematological malignancies (Mitelman et al, 2005) . Whereas most of these genes only have been reported to be involved in one, or a few, chromosomal abnormalities, some have been found to be quite promiscuous. For example, ETV6 (previously TEL), a member of the ets family of transcription factors located at 12p13, has been shown to have several different partners in acute lymphoblastic leukaemias (ALLs), acute myeloid leukaemias (AMLs), chronic myeloproliferative disorders, and myelodysplastic syndromes (MDS). In fact, ETV6 has to date been shown to be rearranged with more than 20 different genes, often encoding tyrosine kinases or transcription factors, in malignant haematological disorders as well as in solid tumours (Bohlander, 2005; Mitelman et al, 2005) .
The molecular characterisation of the various chimaeras has shown that different regions of ETV6 may be involved in the translocations and that the functional outcomes hence are quite variable. Fusion of the 5' region of ETV6 to the 3' region of the partner gene can influence the functional activity of the latter gene, as seen in t(5;12)(q32;p13), complex rearrangements between 9q34 and 12p13, t(9;12)(p24;p13), and t(12;21)(p13;q22), involving PDGFRB, ABL1, JAK2, and RUNX1, respectively. The 5' part of ETV6 can also drive the transcription of a structurally intact partner gene as in t(3;12)(q26;p13) with MDS1/EVI1 and in t(12;13)(p13;q12) with the homeobox gene CDX2. In contrast, the 3' part of ETV6 has been shown to be fused to the 5' part of the partner gene only in a few rearrangements, i.e., the 4 t(4;12)(q12;p13), t(7;12)(q36;p13), t(9;12)(p13;p13), t(12;13)(p13;q14), and t(12;22)(p13;q12), involving the CHIC2, HLXB9, PAX5, TTL, and MN1 genes, respectively (Bohlander, 2005) . These latter fusions most likely have an impact on the function of the HLH and ETS DNA binding domains of ETV6, which are still present in the hybrids.
Another category of ETV6 fusions seems to be "unproductive", i.e., includes chimaeras that do not result in functional products (Bohlander, 2005) . We here present a further example of an unproductive ETV6 fusion, consisting of exons 1 and 2 of ETV6 and a sequence from intron 1 of the BAZ2A gene, in a paediatric pre-B ALL.
Patient, materials and methods
Case history and cytogenetic findings
A previously healthy 3-year-old girl was admitted to hospital in July 2004 because of fever, fatigue, and petechiae. The clinical examination revealed hepatosplenomegaly but no signs of central nervous system disease, mediastinal mass, or enlarged lymph nodes. The peripheral blood values were haemoglobin 64 g/l, white blood cell count 5.6 x 10 9 /l, and thrombocytes 10 x 10 9 /l. The bone marrow (BM) was hypercellular, containing blasts of L2 morphology.
Flow cytometric two-colour analysis showed that 80% of the BM cells were positive for CD19, CD10, CD22, CD38, cytCD79a, and TdT but negative for CD34, CD20, cytIgM, and myeloid markers. A diagnosis of pre-B ALL was made. A monoclonal TCR-gamma gene rearrangement was identified and characterised, which -in parallel with flow cytometric analysis -was used for evaluating minimal residual disease by real time PCR. She started treatment according to the Nordic ALL-2000 protocol for standard intensive patients (drugs and dosages as in the Nordic ALL-1992 protocol; Gustafsson et al, 2000) , and achieved complete remission (CR) on day 15. She remains in CR 18 months after the diagnosis. 
RACE and RT-PCR analyses
Total RNA was extracted from the BM cells using the Trizol reagent according to the manufacturer's instructions (Invitrogen, Carlsbad, CA). The 5´-and 3´-RACE were performed on 1 µg total RNA by the use of the Smart RACE cDNA amplification kit (BD Biosciences, Stockholm, Sweden) according to the manufacturer's protocol. For 5´-RACE, the Universal Primer A Mix (UPM) and the ETV6 reverse primer TEL-34F were used in first round PCR (the ETV6 and BAZ2A primers utilised for PCR amplification and sequence analyses are listed in Table I ). The second round PCR was performed with the Nested Universal Primer A (NUP) and the ETV6 reverse primer TEL-47F. For 3´-RACE, the UPM and the ETV6 forward primer 6 ETV6-171F were used in first round PCR; the second round PCR was performed with the NUP and the forward primer ETV6-242F. Fifteen µL of the PCR products were analysed by electrophoresis through 1.3 % agarose gels, stained with ethidium bromide, and photographed.
For (Table I) , and 2 µL of the cDNA. Two µL of the first PCR product were then used as template in the second PCR with inner primer combinations ( Table   I ). The quality of the cDNA synthesis was examined by amplification of a cDNA fragment of the ABL1 gene (Panagopoulos et al, 2001 ). The PCR products were run on a PCT-200 DNA Engine (MJ Research, Waltham, MA), and all amplifications had an identical cycling profile:
an initial denaturation at 94 o C for 5 min, followed by 30 cycles of 1 min at 94 o C, 1 min at 60 o C, and 1 min at 72 o C, and a final extension for 10 min at 72 o C. For sequence analyses, the RT-PCR-amplified fragments were purified using the Qiagen gel extraction kit (Qiagen, Hilden, Germany) and directly sequenced using the dideoxy procedure with an ABI Prism BigDye terminator v1.1 cycle sequencing kit (PE Applied Biosystems, Foster City, CA) on the Applied Biosystems Model 3100-Avant DNA sequencing system. The BLAST software was used for computer analysis of the sequence data (http://www.ncbi.nlm.nih.gov/BLAST/).
The identified sequence (see below) has been submitted to the EMBL Nucleotide Sequence Database (http://www.ebi.ac.uk), and has been assigned the accession number AM181353.
Results
The interphase FISH analysis with the TEL/AML1 probe revealed a split signal of ETV6 in 20% of the investigated nuclei, indicating that the translocation breakpoint at 12p13 was upstream of exon 4 of ETV6 (Fig 1) . Although the break in principle could be telomeric to ETV6, this gene was considered a likely target of the observed t(?1;12)(q42;p13). Hence, 5´-and 3´-RACE methodologies were utilised in order to find the putative partner gene to ETV6.
Whereas 5´-RACE only amplified normal ETV6 cDNA fragments, 3´-RACE showed a novel sequence fused to exon 2 of ETV6 (Fig 2) in addition to normal ETV6 transcripts, with the latter indicating that the wild type ETV6 was not deleted. Database searches (http://www.ncbi.nlm.nih.gov/) revealed that this fragment corresponds to a sequence on BAC RP11-369C14 (accession number AC090681) which maps to 12q13. Co-hybridization of this BAC with the TEL/AML1 probe revealed a fusion signal of the TEL probe and the BAC RP11-369C14 (Fig 1) . Subsequently, the BLAST analysis showed that the fusion point is in intron 1 of the BAZ2A gene, which is located in the BAC. Thus, the t(?1;12) was not a simple translocation; a cytogenetically cryptic rearrangement between 12p13 and 12q13 had also occurred.
The ETV6/BAZ2A cDNA fragment was confirmed by RT-PCR (Fig 3) using a forward primer (exon 1) specific for ETV6 and a reverse primer (intron 1) specific for the intronic sequence of BAZ2A (ETV6-171F and BAZ2Aintr1-R1, respectively; Table I ). Nested RT-PCR with the forward ETV6 primers ETV6-171F and ETV6-242F (both in exon 1) and the reverse primers BAZ2A-551R and BAZ2A-498R, located in exon 3 of BAZ2A (NM_013449;
http://www.ncbi.nlm.nih.gov/), i.e., distal to intron 1, did not amplify any product, nor did nested RT-PCR with forward primers in exon 1 of BAZ2A (BAZ2A-17F and BAZ2A-115F) and reverse primers in exon 4 of ETV6 (TEL-143R and TEL-135R). These experiments 8 clearly show that there were no ETV6/BAZ2A or BAZ2A/ETV6 fusions on the cDNA level involving exons from both genes; only a transcript consisting of exons 1 and 2 of ETV6 fused to a sequence of intron 1 of BAZ2A was present.
Discussion
The ETV6/BAZ2A transcript identified in the present study is not expected to produce any chimaeric protein. However, it may code for a truncated form of ETV6, consisting of 54 aa from ETV6 followed by 16 aa from the intronic sequence of BAZ2A. This chimaera as such could be of pathogenetic importance. Alternatively -or additionally -the chromosomal rearrangement might deregulate BAZ2A by either activating a cryptic promoter located upstream of exon 2 of BAZ2A or through coming under the control of the ETV6 promoter. The leukemogenic impact of a putative BAZ2A deregulation is currently unknown because the function of the BAZ2A gene, which is quite ubiquitously expressed and belongs to a family of bromodomain genes, is not well elucidated (Jones et al, 2000; Poot et al, 2000) . However, it is known that the mouse homologue Tip5 codes for a protein that is involved in chromatin remodelling (Strohner et al, 2001 ).
The chimaeric ETV6/BAZ2A is similar to the ETV6/STL and ETV6/MDS2 fusions, which have been found in a cell line derived from a pre-B-ALL carrying a t(6;12)(q23;p13) (Sato et al, 1997) and in an MDS with a t(1;12)(p36;p13) , respectively, in the sense that they are all predicted to code for a short ETV6 protein, containing the first 54 aa, followed by only a few aa. In the present case, 16 aa from the BAZ2A gene are present, whereas 4 and 14 aa of STL and MDS2, respectively, follow ETV6 in the fusions involving the latter genes (Sato et al, 1997; Odero et al, 2002) . There are also similarities to three other ETV6 fusions. In the ETV6/PER1 hybrid, generated through the t(12;17)(p13;p13) in AML (Penas et al, 2003) , exon 1 of ETV6 is fused to the anti-sense strand of PER1. Similarly, the 9 first two exons of ETV6 have been shown to be rearranged with the anti-sense strand of LOC115548 at 5q13 in a complex rearrangement in a case of AML (Belloni et al, 2004) .
Furthermore, out-of-frame ETV6 chimaeric transcripts involving the ACSL6 (ASC2) gene have been reported in AML and MDS with t(5;12)(q31;p13) (Yagasaki et al, 1999) . None of these ETV6 rearrangements are expected to code for any functional products. Thus, formation of a fusion protein does not seem to be the pathogenetically important outcome of these translocations. However, it should be stressed that no functional studies of these "abortive"
ETV6 rearrangements have, as yet, been performed.
Another possible leukemogenic mechanism in the present case could be deregulation of a gene in the vicinity of BAZ2A. In fact, it has been shown that the t(5;12), with ACSL6 as the 3' partner, leads to overexpression of IL3, which is located near the breakpoint at 5q31, and that the t(4;12)(q11-12;p13), with CHIC2 as the 5' partner, results in deregulation of the homeobox gene GSH2 close to the 4q11-12 breakpoint (Cools et al, 2002) . Alternatively, the pathogenetic impact may be mediated through haploinsufficiency of ETV6 and/or BAZ2A, as has recently been suggested for the ETV6/LOC115548 hybrid in AML (Belloni et al, 2004 ).
In conclusion, taking into account the various ETV6 abnormalities, including the present one, resulting in non-functional hybrid proteins, it is tempting to postulate that rearrangements of ETV6 as such may play an important pathogenetic role in leukaemia. The asterisk indicates a stop codon. 
